drugset / Trial / NCT03498183

Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology

NCT03498183 ↗

Phase 2/3 Completed 372 enrolled Nantes University Hospital
NaSingle-groupOpen-labelDiagnostic

Summary

The main objective of the study is to show that the addition of ultrasonography to the dual tracer scintigraphy MIBI-Tc99m/Iodine-123 will increase (at least +5%) the negative predictive value compared to the dual tracer scintigraphy alone in detection of malignancy in thyroid nodules ≥15 mm classified as Bethesda III-IV on cytology.

Timeline

Start
2019-01-17
Primary completion
2025-05-07
Completion
2025-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Iodine-123 Diagnostic / imaging agent — Other
Subject MIBI-Tc99m Diagnostic / imaging agent — Other

Indications